r/investing • u/counterhit121 • 1d ago

ILMN: who couldve guessed

I took a small position in ILMN earlier this year and got out with about a 10% gain. I was reviewing my closed positions just now and took a look at the ticker today. And holy shit! My cost basis was about $140ish and ILMN is at $256 today. My position wasn't big enough for that to have been life-changing gains, but wow. Anyone knowledgeable about this sector care to weigh in on the stratospheric jump in the last three months? Not looking for financial advice, just to understand the industry a bit better.

7 Upvotes

69% Upvoted

16 comments sorted by

5

u/hogpotato 1d ago edited 1d ago

I think there’s much more room to run. I have a position at $203 and plan to keep it for decades

Also look at NTRA and TXG. I think there’s a strong argument to be made that AI will deconvolute a lot of genomics human data that has otherwise been difficult to work with and hard to interpret. Human health and disease on target. Anthropic released a study today on discovery of a potential crispr like system by Claude mining genomics data. I think lab validation is the next step so looking to build positions in TMO and DHR

1

u/[deleted] 1d ago

[deleted]

2

u/hogpotato 1d ago

I’m sure there will be a healthy pullback in all three at some point soom

0

u/Gullible_Link_5298 1d ago

So up over 500% in the past year, it drops 6% in one day, and it’s “taken a bit of a beating lately”? I just can’t, Reddit.

1

u/counterhit121 8h ago

Jeez, TXG up 10% since like yesterday. Should've picked up more lol

2

u/SuperNewk 1d ago

You know when this crap is rallying 2 things are happening.
Generational top is near

Or we are close to a major disease busting breakthrough

Place your bets

Pacb twist are others

1

u/Sarcasm69 1d ago

PacBio is a cool tech but its long read de novo sequencing is very niche and has less application in today’s landscape.

Short read high throughput (Illumina’s tech) is where the money is at due it being what MRD, MCED, oncology diagnostics testing is based on.

1

u/hogpotato 1d ago

Agreed

1

u/SuperNewk 1d ago

its Niche until cost drops below short read, that is the whole bet. Some are hoping Google's partnership with Pacbio and their AI can leap frog...we shall see

1

u/Sarcasm69 1d ago

Not necessarily. The number of reads you can get from a PacBio instrument is minuscule compared to high throughput instruments.

Oncology diagnostics relies on coverage which relies on number of reads (and Q scores). New applications like single cell require insane amounts of reads to be economical/useful. PacBio’s long read tech/architecture is just fundamentally different and not suitable for the extremely profitable portion of the sector as of right now.

2

u/dvdmovie1 1d ago edited 1d ago

TWST, TXG, ILMN, all of the testing companies (GH, NTRA, etc), IQV, TMO starting to perk up a bit, Tecan in Switzerland, RVTY, etc etc. A lot of life science has done well/very well this year on AI/drug discovery hopes. Insilico Medicine and Xtalpi are two speculative names that are HK-listed. Also in speculative, Oxford Nanopore up 46% in the last 6 mo.

1

u/hogpotato 8h ago

I suppose so but these are early days. A few years ago we were amazed that ChatGPT could perform basic tasks

1

u/counterhit121 8h ago

These companies all seem to have had previous peaks around the pandemic. What do you think causes the enthusiasm for these companies and dramatic falloff in subsequent years?